| Field | Row 1 |
|---|---|
| adsh | 0001628280-25-023460 |
| cik | 1517022 |
| name | AKEBIA THERAPEUTICS, INC. |
| sic | 2834 |
| countryba | US |
| stprba | MA |
| cityba | CAMBRIDGE |
| zipba | 02142 |
| bas1 | 245 FIRST STREET |
| bas2 | |
| baph | 617-871-2098 |
| countryma | US |
| stprma | MA |
| cityma | CAMBRIDGE |
| zipma | 02142 |
| mas1 | 245 FIRST STREET |
| mas2 | |
| countryinc | US |
| stprinc | DE |
| ein | 208756903 |
| former | |
| changed | |
| afs | 2-ACC |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250508 |
| accepted | 2025-05-08 07:29:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | akba-20250331_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0001628280-25-023460 | 20240331 | Cost Of Revenue | 11605000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Accrued Liabilities Current | 63460000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Accrued Liabilities Current | 71337000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Additional Paid In Capital Common Stock | 1696821000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Amortization Of Intangible Assets | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Assets | 220670000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Assets Current | 203782000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 44579000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 115059000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Earnings Per Share Diluted | -0.0900 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Earnings Per Share Diluted | 0.0300 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Increase Decrease In Accounts Payable | -7501000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Increase Decrease In Contract With Customer Liability | 1241000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Increase Decrease In Other Noncurrent Liabilities | 365000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -1412000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Liabilities | 285604000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Liabilities And Stockholders Equity | 310185000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Liabilities Current | 80914000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | License Expense | 701000.0000 | USD | 1 | 0001628280-25-023460 | |||
| 0001628280-25-023460 | 20240331 | Net Cash Provided By Used In Financing Activities | 18475000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Net Cash Provided By Used In Operating Activities | -19432000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Other Assets Noncurrent | 1400000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= M E D I C E Arzneimittel Putter Gmb H Co K G; Product Or Service= License; | ||
| 0001628280-25-023460 | 20250331 | Other Nonoperating Income Expense | 213000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Payments To Acquire Property Plant And Equipment | 18000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Proceeds From Issuance Of Common Stock Net Of Issuance Costs | 18740000.0000 | USD | 1 | 0001628280-25-023460 | |||
| 0001628280-25-023460 | 20250331 | Proceeds From Issuance Of Debt | 10000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Repayments Of Debt | 36726000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Research And Development Expense | 9731000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Restructuring Charges | 58000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= M E D I C E Arzneimittel Putter Gmb H Co K G; Product Or Service= Supply Agreement; | ||
| 0001628280-25-023460 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 1169000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Japan Tobacco Incorporation And Torii Pharmaceutical Company Limited; Product Or Service= License Collaboration And Other Revenue; | ||
| 0001628280-25-023460 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 1545000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= License Collaboration And Other Revenue; | ||
| 0001628280-25-023460 | 20231231 | Stockholders Equity | 1578358000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-023460 | 20250331 | Stockholders Equity | 24581000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Stockholders Equity | 6000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Net Unrealized Investment Gain Loss; | ||
| 0001628280-25-023460 | 20250331 | Stockholders Equity | 1696821000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-023460 | 20250331 | Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | 1660547.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-023460 | 20240331 | Stock Issued During Period Value Stock Options Exercised | 141000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Stock Issued During Period Value Stock Options Exercised | 141000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-023460 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 204955151.0000 | shares | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Accounts Receivable Credit Loss Expense | 0.0000 | USD | 1 | 0001628280-25-023460 | |||
| 0001628280-25-023460 | 20250331 | Accounts Receivable Net Current | 0.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= M E D I C E Arzneimittel Putter Gmb H Co K G; Product Or Service= License; | ||
| 0001628280-25-023460 | 20250331 | Accounts Receivable Net Current | 0.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Mitsubishi Tanabe Pharma Corporation; Type Of Arrangement= Development And Commercialize Research And License Agreement; | ||
| 0001628280-25-023460 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | 6000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 2360000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-023460 | 20231231 | Common Stock Shares Outstanding | 194582539.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-023460 | 20250331 | Common Stock Shares Outstanding | 261644590.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-023460 | 20240331 | Comprehensive Income Net Of Tax | -17985000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Contract With Customer Refund Liability Noncurrent | 38013000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Cost Of Revenue | 7625000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Gain Loss On Sale Of Property Plant Equipment | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Gains Losses On Extinguishment Of Debt | -517000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Increase Decrease In Accounts Payable | -2234000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Increase Decrease In Other Noncurrent Assets | 613000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Interest Income Expense Nonoperating Net | -2498000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Interest Income Expense Nonoperating Net | -2498000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20240331 | Inventory Write Down | 590000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Inventory Write Down | 163000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | License Expense | 711000.0000 | USD | 1 | 0001628280-25-023460 | |||
| 0001628280-25-023460 | 20240331 | License Expense | 711000.0000 | USD | 1 | 0001628280-25-023460 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20250331 | Long Term Debt Noncurrent | 46511000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Non Cash Financing Activities Issuance Of Warrants | 2199000.0000 | USD | 1 | 0001628280-25-023460 | |||
| 0001628280-25-023460 | 20241231 | Other Liabilities Noncurrent | 4749000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Preferred Stock Shares Authorized | 25000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Proceeds From Stock Options Exercised | 141000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Proceeds From Stock Options Exercised | 482000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Restructuring Charges | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= M E D I C E Arzneimittel Putter Gmb H Co K G; Product Or Service= License Collaboration And Other Revenue Royalties; | ||
| 0001628280-25-023460 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 1598000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited; Product Or Service= License Collaboration And Other Revenue; | ||
| 0001628280-25-023460 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= M E D I C E Arzneimittel Putter Gmb H Co K G; Product Or Service= License Collaboration And Other Revenue Royalties; | ||
| 0001628280-25-023460 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 43757000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Auryxia; | ||
| 0001628280-25-023460 | 20250331 | Selling General And Administrative Expense | 25742000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Stockholders Equity | 2000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-023460 | 20240331 | Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | 1237718.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-023460 | 20250331 | Stock Issued During Period Value New Issues | 64907000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Straight Line Rent | -1104000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Accounts Payable Current | 15180000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Accounts Payable Current | 0.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Mitsubishi Tanabe Pharma Corporation; Type Of Arrangement= Development And Commercialize Research And License Agreement; | ||
| 0001628280-25-023460 | 20240331 | Amortization Of Intangible Assets | 9011000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Assets | 310185000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Common Stock Shares Outstanding | 209454149.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-023460 | 20250331 | Common Stock Shares Outstanding | 261644590.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Contractual Arrangement Royalties Agreement Noncash Royalty Revenue | 391000.0000 | USD | 1 | 0001628280-25-023460 | |||
| 0001628280-25-023460 | 20250331 | Contractual Arrangement Royalties Agreement Noncash Royalty Revenue | 369000.0000 | USD | 1 | 0001628280-25-023460 | |||
| 0001628280-25-023460 | 20250331 | Goodwill | 59044000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Increase Decrease In Accrued Liabilities | -15045000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Increase Decrease In Inventories | 4953000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Increase Decrease In Operating Lease Liability | -731000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -2212000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Interest Income Expense Nonoperating Net | -7770000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20241231 | Liabilities | 269855000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Net Cash Provided By Used In Financing Activities | 74942000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Net Income Loss | -17985000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Net Income Loss | 6112000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Non Cash Financing Activities Unpaid Issuance Costs | 522000.0000 | USD | 1 | 0001628280-25-023460 | |||
| 0001628280-25-023460 | 20240331 | Operating Income Loss | -14936000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Operating Lease Liability Noncurrent | 3547000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Preferred Stock Shares Authorized | 25000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Proceeds From Sale Of Property Plant And Equipment | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Property Plant And Equipment Net | 2200000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Repayments Of Debt | 462000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 32607000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 1200000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Japan Tobacco Incorporation And Torii Pharmaceutical Company Limited; Type Of Arrangement= Sublicense Agreement; | ||
| 0001628280-25-023460 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 1598000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= License Collaboration And Other Revenue; | ||
| 0001628280-25-023460 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 400000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Mitsubishi Tanabe Pharma Corporation; Product Or Service= License Collaboration And Other Revenue Royalties; | ||
| 0001628280-25-023460 | 20240331 | Selling General And Administrative Expense | 25438000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20231231 | Stockholders Equity | 2000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-023460 | 20241231 | Stockholders Equity | -49185000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Stockholders Equity | 2000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-023460 | 20240331 | Stock Issued During Period Shares Employee Stock Purchase Plans | 92321.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-023460 | 20240331 | Stock Issued During Period Shares New Issues | 13261311.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-023460 | 20250331 | Stock Issued During Period Shares Stock Options Exercised | 604325.0000 | shares | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Stock Issued During Period Value New Issues | 18740000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Stock Issued During Period Value New Issues | 18740000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-023460 | 20240331 | Straight Line Rent | -1017000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 204955151.0000 | shares | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Additional Paid In Capital Common Stock | 1629167000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 53550000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Common Stock Shares Authorized | 350000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Common Stock Value | 2000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20210228 | Contractual Arrangement Royalties Agreement Liability Noncurrent | 44800000.0000 | USD | 0 | 0001628280-25-023460 | |||
| 0001628280-25-023460 | 20250331 | Contractual Arrangement Royalties Agreement Liability Noncurrent | 51549000.0000 | USD | 0 | 0001628280-25-023460 | |||
| 0001628280-25-023460 | 20241231 | Contract With Customer Liability Current | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Contract With Customer Liability Current | 1241000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Gains Losses On Extinguishment Of Debt | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -17985000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Increase Decrease In Inventories | 4434000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Interest Income Expense Nonoperating Net | 0.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Vifor International Limited; | ||
| 0001628280-25-023460 | 20250331 | Interest Income Expense Nonoperating Net | -7770000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Liabilities And Stockholders Equity | 220670000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Liabilities Current | 91227000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Net Income Loss | -17985000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20240331 | Net Income Loss | -17985000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-023460 | 20250331 | Operating Expenses | 36197000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Operating Income Loss | 13514000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Operating Lease Right Of Use Asset | 8218000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Other Assets Noncurrent | 1400000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= M E D I C E Arzneimittel Putter Gmb H Co K G; Product Or Service= License; | ||
| 0001628280-25-023460 | 20240331 | Payments Of Debt Issuance Costs | 750000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Prepaid Expense And Other Assets Current | 11350000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Prepaid Expense And Other Assets Current | 9138000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 1186000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Japan Tobacco Incorporation And Torii Pharmaceutical Company Limited; Product Or Service= License Collaboration And Other Revenue; | ||
| 0001628280-25-023460 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 57336000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= M E D I C E Arzneimittel Putter Gmb H Co K G; Product Or Service= Supply Agreement; | ||
| 0001628280-25-023460 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 55791000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Product; | ||
| 0001628280-25-023460 | 20231231 | Stockholders Equity | -30584000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20231231 | Stockholders Equity | 6000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Net Unrealized Investment Gain Loss; | ||
| 0001628280-25-023460 | 20240331 | Stockholders Equity | -27258000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Stockholders Equity | 6000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Net Unrealized Investment Gain Loss; | ||
| 0001628280-25-023460 | 20240331 | Stockholders Equity | 1599669000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-023460 | 20241231 | Stockholders Equity | 6000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Net Unrealized Investment Gain Loss; | ||
| 0001628280-25-023460 | 20241231 | Stockholders Equity | 1629167000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-023460 | 20250331 | Stock Issued During Period Shares New Issues | 34437364.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-023460 | 20250331 | Stock Issued During Period Value Employee Stock Purchase Plan | 78000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Accounts Payable Current | 0.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= M E D I C E Arzneimittel Putter Gmb H Co K G; Product Or Service= License; | ||
| 0001628280-25-023460 | 20250331 | Accounts Receivable Credit Loss Expense | 702000.0000 | USD | 1 | 0001628280-25-023460 | |||
| 0001628280-25-023460 | 20250331 | Amortization Of Intangible Assets | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001628280-25-023460 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Common Stock Shares Authorized | 350000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Common Stock Shares Outstanding | 224848992.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Comprehensive Income Net Of Tax | 6112000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Contractual Arrangement Royalties Agreement Settlement Liability Noncurrent | 47440000.0000 | USD | 0 | 0001628280-25-023460 | |||
| 0001628280-25-023460 | 20241231 | Contract With Customer Refund Liability Current | 2274000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Contract With Customer Refund Liability Current | 5991000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Cost Of Goods And Services Sold Amortization | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Depreciation | 314000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Earnings Per Share Basic | -0.0900 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Gains Losses On Extinguishment Of Debt | -500000.0000 | USD | 1 | us-gaap/2024 | Credit Facility= Term Loan; Debt Instrument= Tranche A And B; Guarantee Obligations By Nature= Keryx; Line Of Credit Facility= Biopharma Credit Investments V Master Limited Partner; Type Of Arrangement= Collateral Agent Pharmakon; | ||
| 0001628280-25-023460 | 20250331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | 6112000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20240331 | Increase Decrease In Other Noncurrent Liabilities | -1600000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | License Expense | 701000.0000 | USD | 1 | 0001628280-25-023460 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20240331 | Net Cash Provided By Used In Investing Activities | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Non Cash Financing Activities Issuance Of Warrants | 4846000.0000 | USD | 1 | 0001628280-25-023460 | |||
| 0001628280-25-023460 | 20250331 | Other Liabilities Noncurrent | 5114000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Payments To Acquire Property Plant And Equipment | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Research And Development Expense | 9731000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20250331 | Research And Development Expense | 9754000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Research And Development Expense | 9754000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20241231 | Retained Earnings Accumulated Deficit | -1678360000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20151130 | Revenue From Contract With Customer Excluding Assessed Tax | 7300000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Mitsubishi Tanabe Pharma Corporation; | ||
| 0001628280-25-023460 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= M E D I C E Arzneimittel Putter Gmb H Co K G; Product Or Service= License Collaboration And Other Revenue; | ||
| 0001628280-25-023460 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 57336000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 7000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= M E D I C E Arzneimittel Putter Gmb H Co K G; Product Or Service= License Collaboration And Other Revenue; | ||
| 0001628280-25-023460 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 12034000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Vafseo; | ||
| 0001628280-25-023460 | 20231231 | Stockholders Equity | -1608950000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-023460 | 20241231 | Stockholders Equity | -1678360000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-023460 | 20240331 | Stock Issued During Period Shares Stock Options Exercised | 280260.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-023460 | 20240331 | Stock Issued During Period Value Employee Stock Purchase Plan | 70000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-023460 | 20240331 | Write Off Of Deferred Debt Issuance Cost | 294000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Write Off Of Deferred Debt Issuance Cost | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 2187000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 2187000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-023460 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 43622000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 61509000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001628280-25-023460 | 20170531 | Common Stock Shares Issued | 3571429.0000 | shares | 0 | us-gaap/2024 | Counterparty Name= Vifor International Limited; Type Of Arrangement= License Agreement; | ||
| 0001628280-25-023460 | 20241231 | Common Stock Shares Issued | 224848992.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Common Stock Value | 2000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Contract With Customer Refund Liability Noncurrent | 34420000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Earnings Per Share Basic | 0.0300 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Fair Value Adjustment Of Warrants | 129000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20250331 | Fair Value Adjustment Of Warrants | -155000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Gains Losses On Extinguishment Of Debt | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20250331 | Increase Decrease In Accrued Liabilities | 2771000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Interest Income Expense Nonoperating Net | 5400000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Vifor International Limited; | ||
| 0001628280-25-023460 | 20241231 | Inventory Net | 16243000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Inventory Write Down | 600000.0000 | USD | 1 | us-gaap/2024 | Public Utilities Inventory= Auryxia Drug Substance; | ||
| 0001628280-25-023460 | 20241231 | Long Term Debt Noncurrent | 38693000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Non Cash Financing Activities Unpaid Issuance Costs | 0.0000 | USD | 1 | 0001628280-25-023460 | |||
| 0001628280-25-023460 | 20250331 | Operating Lease Liability Noncurrent | 2123000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Other Assets Noncurrent | 38341000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Other Nonoperating Income Expense | 95000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Other Nonoperating Income Expense | 213000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20250331 | Payments Of Debt Issuance Costs | 63000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Proceeds From Issuance Of Common Stock Net Of Issuance Costs | 64907000.0000 | USD | 1 | 0001628280-25-023460 | |||
| 0001628280-25-023460 | 20240331 | Proceeds From Issuance Of Debt | 37000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Proceeds From Stock Plans | 70000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Property Plant And Equipment Net | 1904000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Restructuring Charges | 58000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20231231 | Revenue From Contract With Customer Excluding Assessed Tax | 10000000.0000 | USD | 4 | us-gaap/2024 | Counterparty Name= M E D I C E Arzneimittel Putter Gmb H Co K G; Product Or Service= License Collaboration And Other Revenue; | ||
| 0001628280-25-023460 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 400000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Mitsubishi Tanabe Pharma Corporation; Product Or Service= License Collaboration And Other Revenue Royalties; | ||
| 0001628280-25-023460 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 31009000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Auryxia; | ||
| 0001628280-25-023460 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 1200000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Japan Tobacco Incorporation And Torii Pharmaceutical Company Limited; Type Of Arrangement= Sublicense Agreement; | ||
| 0001628280-25-023460 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 369000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Mitsubishi Tanabe Pharma Corporation; Product Or Service= License Collaboration And Other Revenue; | ||
| 0001628280-25-023460 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 1545000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Mitsubishi Tanabe Pharma Corporation And Otsuka Pharmaceutical Company Limited; Product Or Service= License Collaboration And Other Revenue; | ||
| 0001628280-25-023460 | 20240331 | Share Based Compensation | 2360000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Stockholders Equity | 2000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-023460 | 20250331 | Stock Issued During Period Shares Employee Stock Purchase Plans | 93362.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-023460 | 20250331 | Stock Issued During Period Value Employee Stock Purchase Plan | 78000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-023460 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 482000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 482000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-023460 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 241602853.0000 | shares | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Accounts Receivable Net Current | 34368000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 2360000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Assets Current | 113831000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -957000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Common Stock Shares Issued | 261644590.0000 | shares | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Cost Of Goods And Service Excluding Depreciation Depletion And Amortization | 2594000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Cost Of Goods And Services Sold Amortization | 9011000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Depreciation | 364000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Derivative Liabilities Noncurrent | 5176000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Derivative Liabilities Noncurrent | 7220000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Gain Loss On Sale Of Property Plant Equipment | 172000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | 6112000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Increase Decrease In Accounts Receivable | -12670000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Increase Decrease In Contract With Customer Liability | 695000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Inventory Write Down | 200000.0000 | USD | 1 | us-gaap/2024 | Public Utilities Inventory= Auryxia Drug Substance; | ||
| 0001628280-25-023460 | 20250331 | Net Income Loss | 6112000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20250331 | Net Income Loss | 6112000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-023460 | 20250331 | Noncash Interest Expense | 6253000.0000 | USD | 1 | 0001628280-25-023460 | |||
| 0001628280-25-023460 | 20240331 | Operating Expenses | 35938000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Other Assets Noncurrent | 37377000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Preferred Stock Par Or Stated Value Per Share | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Proceeds From Sale Of Property Plant And Equipment | 172000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Proceeds From Stock Plans | 78000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Retained Earnings Accumulated Deficit | -1672248000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 31009000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Product; | ||
| 0001628280-25-023460 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Vafseo; | ||
| 0001628280-25-023460 | 20250331 | Share Based Compensation | 2187000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Stockholders Equity | -1626935000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-023460 | 20240331 | Stock Issued During Period Value Employee Stock Purchase Plan | 70000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Stock Issued During Period Value New Issues | 64907000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001628280-25-023460 | 20250331 | Accounts Payable Current | 12658000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Accounts Receivable Net Current | 61538000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | 6000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Amortization Of Intangible Assets | 9011000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20241231 | Cash And Cash Equivalents At Carrying Value | 51870000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Cash And Cash Equivalents At Carrying Value | 113374000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20241231 | Common Stock Shares Outstanding | 224848992.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-023460 | 20241231 | Contractual Arrangement Royalties Agreement Liability Noncurrent | 52066000.0000 | USD | 0 | 0001628280-25-023460 | |||
| 0001628280-25-023460 | 20241231 | Contractual Arrangement Royalties Agreement Settlement Liability Noncurrent | 46697000.0000 | USD | 0 | 0001628280-25-023460 | |||
| 0001628280-25-023460 | 20250331 | Cost Of Goods And Service Excluding Depreciation Depletion And Amortization | 7625000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Fair Value Adjustment Of Warrants | 129000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Fair Value Adjustment Of Warrants | -155000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20240331 | Gains Losses On Extinguishment Of Debt | -517000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20241231 | Goodwill | 59044000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -17985000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20250331 | Increase Decrease In Accounts Receivable | 27872000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Increase Decrease In Operating Lease Liability | -1310000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Increase Decrease In Other Noncurrent Assets | -54000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Inventory Net | 19732000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Net Cash Provided By Used In Investing Activities | 154000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Net Cash Provided By Used In Operating Activities | -13587000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Noncash Interest Expense | 326000.0000 | USD | 1 | 0001628280-25-023460 | |||
| 0001628280-25-023460 | 20240331 | Operating Income Loss | -14936000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20250331 | Operating Income Loss | 13514000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20250331 | Operating Lease Right Of Use Asset | 7114000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20240331 | Other Nonoperating Income Expense | 95000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20250331 | Preferred Stock Par Or Stated Value Per Share | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001628280-25-023460 | 20250331 | Restructuring Charges | 0.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 32607000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 412000.0000 | USD | 1 | us-gaap/2024 | Counterparty Name= Mitsubishi Tanabe Pharma Corporation; Product Or Service= License Collaboration And Other Revenue; | ||
| 0001628280-25-023460 | 20240331 | Selling General And Administrative Expense | 25438000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20250331 | Selling General And Administrative Expense | 25742000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001628280-25-023460 | 20250331 | Stockholders Equity | -1672248000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001628280-25-023460 | 20250331 | Stock Issued During Period Shares Stock Options Exercised | 604325.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001628280-25-023460 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 235497720.0000 | shares | 1 | us-gaap/2024 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Increase Decrease In Accounts Receivable | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts Receivable | The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. |
| Stock Issued During Period Value Stock Options Exercised | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Stock Options Exercised | Value of stock issued as a result of the exercise of stock options. |
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Increase Decrease In Other Noncurrent Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Other Noncurrent Assets | Amount of increase (decrease) in noncurrent assets classified as other. |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Payments To Acquire Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. |
| Comprehensive Income Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Increase Decrease In Contract With Customer Liability | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Contract with Customer, Liability | Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. |
| Interest Income Expense Nonoperating Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Interest Income (Expense), Nonoperating | Amount of interest income (expense) classified as nonoperating. |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Proceeds From Stock Options Exercised | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Stock Options Exercised | Amount of cash inflow from exercise of option under share-based payment arrangement. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Accounts Receivable Net Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Accounts Receivable, after Allowance for Credit Loss, Current | Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Payments Of Debt Issuance Costs | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments of Debt Issuance Costs | The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. |
| Stock Issued During Period Value Employee Stock Purchase Plan | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Employee Stock Purchase Plan | Aggregate change in value for stock issued during the period as a result of employee stock purchase plan. |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Accounts Receivable Credit Loss Expense | 0001628280-25-023460 | 1 | 0 | monetary | D | D | Accounts Receivable, Credit Loss Expense | Accounts Receivable, Credit Loss Expense |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | I | C | Accumulated Other Comprehensive Income (Loss), Net of Tax | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Common Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Operating Lease Right Of Use Asset | us-gaap/2024 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Other Assets Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets, Noncurrent | Amount of noncurrent assets classified as other. |
| Accrued Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Liabilities, Current | Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Contractual Arrangement Royalties Agreement Noncash Royalty Revenue | 0001628280-25-023460 | 1 | 0 | monetary | D | C | Contractual Arrangement, Royalties Agreement, Noncash Royalty Revenue | Contractual Arrangement, Royalties Agreement, Noncash Royalty Revenue |
| Contract With Customer Refund Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Contract with Customer, Refund Liability, Noncurrent | Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as noncurrent. |
| Cost Of Revenue | us-gaap/2024 | 0 | 0 | monetary | D | D | Cost of Revenue | The aggregate cost of goods produced and sold and services rendered during the reporting period. |
| Derivative Liabilities Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Derivative Liability, Noncurrent | Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset. |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Preferred Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Issued | Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. | |
| Proceeds From Issuance Of Debt | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Issuance of Debt | The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. |
| Restructuring Charges | us-gaap/2024 | 0 | 0 | monetary | D | D | Restructuring Charges | Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. |
| Selling General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Selling, General and Administrative Expense | The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | us-gaap/2024 | 0 | 0 | shares | D | Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures | Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. | |
| Contractual Arrangement Royalties Agreement Settlement Liability Noncurrent | 0001628280-25-023460 | 1 | 0 | monetary | I | C | Contractual Arrangement, Royalties Agreement, Settlement Liability, Noncurrent | Contractual Arrangement, Royalties Agreement, Settlement Liability, Noncurrent |
| Noncash Interest Expense | 0001628280-25-023460 | 1 | 0 | monetary | D | D | Noncash Interest Expense | Noncash interest expense. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Increase Decrease In Inventories | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Inventories | The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Inventory Write Down | us-gaap/2024 | 0 | 0 | monetary | D | D | Inventory Write-down | Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. |
| Preferred Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Preferred Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Proceeds From Sale Of Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Sale of Property, Plant, and Equipment | The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. |
| Write Off Of Deferred Debt Issuance Cost | us-gaap/2024 | 0 | 0 | monetary | D | D | Deferred Debt Issuance Cost, Writeoff | Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt. |
| Contractual Arrangement Royalties Agreement Liability Noncurrent | 0001628280-25-023460 | 1 | 0 | monetary | I | C | Contractual Arrangement, Royalties Agreement, Liability, Noncurrent | Contractual Arrangement, Royalties Agreement, Liability, Noncurrent |
| Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Goodwill | Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Operating Expenses | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Expenses | Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Other Liabilities Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Other Liabilities, Noncurrent | Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Repayments Of Debt | us-gaap/2024 | 0 | 0 | monetary | D | C | Repayments of Debt | Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Cost Of Goods And Service Excluding Depreciation Depletion And Amortization | us-gaap/2024 | 0 | 0 | monetary | D | D | Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization | Cost of product sold and service rendered, excluding depreciation, depletion, and amortization. |
| Inventory Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Inventory, Net | Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. |
| Proceeds From Stock Plans | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Stock Plans | The cash inflow associated with the amount received from the stock plan during the period. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Stock Issued During Period Shares New Issues | us-gaap/2024 | 0 | 0 | shares | D | Stock Issued During Period, Shares, New Issues | Number of new stock issued during the period. | |
| License Expense | 0001628280-25-023460 | 1 | 0 | monetary | D | D | License Expense | License expense. |
| Non Cash Financing Activities Issuance Of Warrants | 0001628280-25-023460 | 1 | 0 | monetary | D | C | Non-Cash Financing Activities, Issuance of Warrants | Non-Cash Financing Activities, Issuance of Warrants |
| Additional Paid In Capital Common Stock | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital, Common Stock | Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. |
| Amortization Of Intangible Assets | us-gaap/2024 | 0 | 0 | monetary | D | D | Amortization of Intangible Assets | The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Contract With Customer Refund Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Contract with Customer, Refund Liability, Current | Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer, classified as current. |
| Cost Of Goods And Services Sold Amortization | us-gaap/2024 | 0 | 0 | monetary | D | D | Cost, Amortization | Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service. |
| Gains Losses On Extinguishment Of Debt | us-gaap/2024 | 0 | 0 | monetary | D | C | Gain (Loss) on Extinguishment of Debt | Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. |
| Fair Value Adjustment Of Warrants | us-gaap/2024 | 0 | 0 | monetary | D | D | Fair Value Adjustment of Warrants | Amount of expense (income) related to adjustment to fair value of warrant liability. |
| Gain Loss On Sale Of Property Plant Equipment | us-gaap/2024 | 0 | 0 | monetary | D | C | Gain (Loss) on Disposition of Property Plant Equipment | Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. |
| Increase Decrease In Accounts Payable | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable | The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. |
| Increase Decrease In Operating Lease Liability | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Operating Lease Liability | Amount of increase (decrease) in obligation for operating lease. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Preferred Stock, Par or Stated Value Per Share | Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. | |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Contract With Customer Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Contract with Customer, Liability, Current | Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. |
| Depreciation | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation | The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Other Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Nonoperating Income (Expense) | Amount of income (expense) related to nonoperating activities, classified as other. |
| Preferred Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Authorized | The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. | |
| Preferred Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Outstanding | Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. | |
| Stock Issued During Period Shares Employee Stock Purchase Plans | us-gaap/2024 | 0 | 0 | shares | D | Stock Issued During Period, Shares, Employee Stock Purchase Plans | Number of shares issued during the period as a result of an employee stock purchase plan. | |
| Stock Issued During Period Shares Stock Options Exercised | us-gaap/2024 | 0 | 0 | shares | D | Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period | Number of share options (or share units) exercised during the current period. | |
| Stock Issued During Period Value New Issues | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, New Issues | Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. |
| Increase Decrease In Accrued Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accrued Liabilities | The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. |
| Increase Decrease In Other Noncurrent Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Other Noncurrent Liabilities | Amount of increase (decrease) in noncurrent operating liabilities classified as other. |
| Long Term Debt Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Long-Term Debt, Excluding Current Maturities | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. |
| Operating Lease Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. |
| Property Plant And Equipment Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Property, Plant and Equipment, Net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
| Straight Line Rent | us-gaap/2024 | 0 | 0 | monetary | D | C | Straight Line Rent | Difference between actual rental income due and rental income recognized on a straight-line basis. |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. | |
| Non Cash Financing Activities Unpaid Issuance Costs | 0001628280-25-023460 | 1 | 0 | monetary | D | D | Non-Cash Financing Activities, Unpaid Issuance Costs | Non-Cash Financing Activities, Unpaid Issuance Costs |
| Proceeds From Issuance Of Common Stock Net Of Issuance Costs | 0001628280-25-023460 | 1 | 0 | monetary | D | D | Proceeds From Issuance Of Common Stock Net Of Issuance Costs | Proceeds from issuance of common stock net of issuance costs. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0001628280-25-023460 | 2 | 3 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0001628280-25-023460 | 2 | 4 | BS | 0 | H | Inventory Net | us-gaap/2024 | Inventories | 0 |
| 0001628280-25-023460 | 2 | 5 | BS | 0 | H | Accounts Receivable Net Current | us-gaap/2024 | Accounts receivable, net | 0 |
| 0001628280-25-023460 | 2 | 6 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaid expenses and other current assets | 0 |
| 0001628280-25-023460 | 2 | 7 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0001628280-25-023460 | 2 | 8 | BS | 0 | H | Property Plant And Equipment Net | us-gaap/2024 | Property and equipment, net | 0 |
| 0001628280-25-023460 | 2 | 9 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2024 | Operating right-of-use assets | 0 |
| 0001628280-25-023460 | 2 | 10 | BS | 0 | H | Goodwill | us-gaap/2024 | Goodwill | 0 |
| 0001628280-25-023460 | 2 | 11 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2024 | Other long-term assets | 0 |
| 0001628280-25-023460 | 2 | 12 | BS | 0 | H | Assets | us-gaap/2024 | Total assets | 0 |
| 0001628280-25-023460 | 2 | 15 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0001628280-25-023460 | 2 | 16 | BS | 0 | H | Accrued Liabilities Current | us-gaap/2024 | Accrued expenses and other current liabilities | 0 |
| 0001628280-25-023460 | 2 | 17 | BS | 0 | H | Contract With Customer Liability Current | us-gaap/2024 | Current portion of deferred revenue | 0 |
| 0001628280-25-023460 | 2 | 18 | BS | 0 | H | Contract With Customer Refund Liability Current | us-gaap/2024 | Working Capital Fund liability, current portion | 0 |
| 0001628280-25-023460 | 2 | 19 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0001628280-25-023460 | 2 | 20 | BS | 0 | H | Operating Lease Liability Noncurrent | us-gaap/2024 | Long-term operating lease liabilities | 0 |
| 0001628280-25-023460 | 2 | 21 | BS | 0 | H | Long Term Debt Noncurrent | us-gaap/2024 | Long-term debt, net | 0 |
| 0001628280-25-023460 | 2 | 22 | BS | 0 | H | Contractual Arrangement Royalties Agreement Settlement Liability Noncurrent | 0001628280-25-023460 | Liability related to settlement royalties, net of current portion | 0 |
| 0001628280-25-023460 | 2 | 23 | BS | 0 | H | Contractual Arrangement Royalties Agreement Liability Noncurrent | 0001628280-25-023460 | Liability related to sale of future royalties, net of current portion | 0 |
| 0001628280-25-023460 | 2 | 24 | BS | 0 | H | Contract With Customer Refund Liability Noncurrent | us-gaap/2024 | Working Capital Fund liability, net of current portion | 0 |
| 0001628280-25-023460 | 2 | 25 | BS | 0 | H | Derivative Liabilities Noncurrent | us-gaap/2024 | Warrant liability | 0 |
| 0001628280-25-023460 | 2 | 26 | BS | 0 | H | Other Liabilities Noncurrent | us-gaap/2024 | Other long-term liabilities | 0 |
| 0001628280-25-023460 | 2 | 27 | BS | 0 | H | Liabilities | us-gaap/2024 | Total liabilities | 0 |
| 0001628280-25-023460 | 2 | 28 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | Commitments and contingencies (Note 10) | 0 |
| 0001628280-25-023460 | 2 | 30 | BS | 0 | H | Preferred Stock Value | us-gaap/2024 | Preferred stock $0.00001 par value, 25,000,000 shares authorized; no shares issued and outstanding at March 31, 2025 and December 31, 2024 | 0 |
| 0001628280-25-023460 | 2 | 31 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common stock $0.00001 par value; 350,000,000 shares authorized at March 31, 2025 and December 31, 2024; 261,644,590 and 224,848,992 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | 0 |
| 0001628280-25-023460 | 2 | 32 | BS | 0 | H | Additional Paid In Capital Common Stock | us-gaap/2024 | Additional paid-in capital | 0 |
| 0001628280-25-023460 | 2 | 33 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Accumulated other comprehensive income | 0 |
| 0001628280-25-023460 | 2 | 34 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Accumulated deficit | 0 |
| 0001628280-25-023460 | 2 | 35 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total stockholders' equity (deficit) | 0 |
| 0001628280-25-023460 | 2 | 36 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total liabilities and stockholders' equity (deficit) | 0 |
| 0001628280-25-023460 | 3 | 1 | BS | 1 | H | Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | Preferred stock, par value (in dollars per share) | 0 |
| 0001628280-25-023460 | 3 | 2 | BS | 1 | H | Preferred Stock Shares Authorized | us-gaap/2024 | Preferred stock, authorized (in shares) | 0 |
| 0001628280-25-023460 | 3 | 3 | BS | 1 | H | Preferred Stock Shares Issued | us-gaap/2024 | Preferred stock, issued (in shares) | 0 |
| 0001628280-25-023460 | 3 | 4 | BS | 1 | H | Preferred Stock Shares Outstanding | us-gaap/2024 | Preferred stock, outstanding (in shares) | 0 |
| 0001628280-25-023460 | 3 | 5 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common stock, par value (in dollars per share) | 0 |
| 0001628280-25-023460 | 3 | 6 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common stock, authorized (in shares) | 0 |
| 0001628280-25-023460 | 3 | 7 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2024 | Common stock, issued (in shares) | 0 |
| 0001628280-25-023460 | 3 | 8 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common stock, outstanding (in shares) | 0 |
| 0001628280-25-023460 | 4 | 8 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | Total revenues | 0 |
| 0001628280-25-023460 | 4 | 10 | IS | 0 | H | Cost Of Goods And Service Excluding Depreciation Depletion And Amortization | us-gaap/2024 | Cost of product and other revenue | 0 |
| 0001628280-25-023460 | 4 | 11 | IS | 0 | H | Cost Of Goods And Services Sold Amortization | us-gaap/2024 | Amortization of intangible asset | 0 |
| 0001628280-25-023460 | 4 | 12 | IS | 0 | H | Cost Of Revenue | us-gaap/2024 | Total cost of goods sold | 0 |
| 0001628280-25-023460 | 4 | 14 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Research and development | 0 |
| 0001628280-25-023460 | 4 | 15 | IS | 0 | H | Selling General And Administrative Expense | us-gaap/2024 | Selling, general and administrative | 0 |
| 0001628280-25-023460 | 4 | 16 | IS | 0 | H | License Expense | 0001628280-25-023460 | License | 0 |
| 0001628280-25-023460 | 4 | 17 | IS | 0 | H | Restructuring Charges | us-gaap/2024 | Restructuring | 0 |
| 0001628280-25-023460 | 4 | 18 | IS | 0 | H | Operating Expenses | us-gaap/2024 | Total operating expenses | 0 |
| 0001628280-25-023460 | 4 | 19 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Income (loss) from operations | 0 |
| 0001628280-25-023460 | 4 | 21 | IS | 0 | H | Interest Income Expense Nonoperating Net | us-gaap/2024 | Interest expense | 0 |
| 0001628280-25-023460 | 4 | 22 | IS | 0 | H | Other Nonoperating Income Expense | us-gaap/2024 | Other income | 0 |
| 0001628280-25-023460 | 4 | 23 | IS | 0 | H | Fair Value Adjustment Of Warrants | us-gaap/2024 | Change in fair value of warrant liability | 1 |
| 0001628280-25-023460 | 4 | 24 | IS | 0 | H | Gains Losses On Extinguishment Of Debt | us-gaap/2024 | Loss on extinguishment of debt | 0 |
| 0001628280-25-023460 | 4 | 25 | IS | 0 | H | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | Net income (loss) before income taxes | 0 |
| 0001628280-25-023460 | 4 | 26 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net income (loss) | 0 |
| 0001628280-25-023460 | 4 | 27 | IS | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2024 | Comprehensive income (loss) | 0 |
| 0001628280-25-023460 | 4 | 29 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Basic (in dollars per share) | 0 |
| 0001628280-25-023460 | 4 | 30 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Diluted (in dollars per share) | 0 |
| 0001628280-25-023460 | 4 | 32 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | Basic (in shares) | 0 |
| 0001628280-25-023460 | 4 | 33 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Diluted (in shares) | 0 |
| 0001628280-25-023460 | 5 | 10 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Beginning balance (in shares) | 0 |
| 0001628280-25-023460 | 5 | 11 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Beginning balance | 0 |
| 0001628280-25-023460 | 5 | 12 | EQ | 0 | H | Stock Issued During Period Shares New Issues | us-gaap/2024 | Issuance of common stock, net of issuance costs (in shares) | 0 |
| 0001628280-25-023460 | 5 | 13 | EQ | 0 | H | Stock Issued During Period Value New Issues | us-gaap/2024 | Issuance of common stock, net of issuance costs | 0 |
| 0001628280-25-023460 | 5 | 14 | EQ | 0 | H | Stock Issued During Period Shares Employee Stock Purchase Plans | us-gaap/2024 | Proceeds from sale of stock under employee stock purchase plan (in shares) | 0 |
| 0001628280-25-023460 | 5 | 15 | EQ | 0 | H | Stock Issued During Period Value Employee Stock Purchase Plan | us-gaap/2024 | Proceeds from sale of stock under employee stock purchase plan | 0 |
| 0001628280-25-023460 | 5 | 16 | EQ | 0 | H | Stock Issued During Period Shares Stock Options Exercised | us-gaap/2024 | Exercise of options (in shares) | 0 |
| 0001628280-25-023460 | 5 | 17 | EQ | 0 | H | Stock Issued During Period Value Stock Options Exercised | us-gaap/2024 | Exercise of options | 0 |
| 0001628280-25-023460 | 5 | 18 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | Stock-based compensation expense | 0 |
| 0001628280-25-023460 | 5 | 19 | EQ | 0 | H | Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | us-gaap/2024 | Restricted stock unit vesting (in shares) | 0 |
| 0001628280-25-023460 | 5 | 20 | EQ | 0 | H | Net Income Loss | us-gaap/2024 | Net income (loss) | 0 |
| 0001628280-25-023460 | 5 | 21 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Ending balance (in shares) | 0 |
| 0001628280-25-023460 | 5 | 22 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Ending balance | 0 |
| 0001628280-25-023460 | 6 | 2 | CF | 0 | H | Net Income Loss | us-gaap/2024 | Net income (loss) | 0 |
| 0001628280-25-023460 | 6 | 4 | CF | 0 | H | Depreciation | us-gaap/2024 | Depreciation | 0 |
| 0001628280-25-023460 | 6 | 5 | CF | 0 | H | Amortization Of Intangible Assets | us-gaap/2024 | Amortization of intangible asset | 0 |
| 0001628280-25-023460 | 6 | 6 | CF | 0 | H | Accounts Receivable Credit Loss Expense | 0001628280-25-023460 | Bad debt expense | 0 |
| 0001628280-25-023460 | 6 | 7 | CF | 0 | H | Fair Value Adjustment Of Warrants | us-gaap/2024 | Change in fair value of warrant liability | 0 |
| 0001628280-25-023460 | 6 | 8 | CF | 0 | H | Contractual Arrangement Royalties Agreement Noncash Royalty Revenue | 0001628280-25-023460 | Non-cash royalty revenue related to sale of future royalties | 1 |
| 0001628280-25-023460 | 6 | 9 | CF | 0 | H | Noncash Interest Expense | 0001628280-25-023460 | Non-cash interest expense | 0 |
| 0001628280-25-023460 | 6 | 10 | CF | 0 | H | Straight Line Rent | us-gaap/2024 | Non-cash operating lease expense | 1 |
| 0001628280-25-023460 | 6 | 11 | CF | 0 | H | Write Off Of Deferred Debt Issuance Cost | us-gaap/2024 | Non-cash loss on extinguishment of debt | 0 |
| 0001628280-25-023460 | 6 | 12 | CF | 0 | H | Inventory Write Down | us-gaap/2024 | Write-down of inventory | 0 |
| 0001628280-25-023460 | 6 | 13 | CF | 0 | H | Gain Loss On Sale Of Property Plant Equipment | us-gaap/2024 | Gain on the sale of property and equipment | 1 |
| 0001628280-25-023460 | 6 | 14 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Stock-based compensation expense | 0 |
| 0001628280-25-023460 | 6 | 16 | CF | 0 | H | Increase Decrease In Accounts Receivable | us-gaap/2024 | Accounts receivable | 1 |
| 0001628280-25-023460 | 6 | 17 | CF | 0 | H | Increase Decrease In Inventories | us-gaap/2024 | Inventory | 1 |
| 0001628280-25-023460 | 6 | 18 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | Prepaid expenses and other current assets | 1 |
| 0001628280-25-023460 | 6 | 19 | CF | 0 | H | Increase Decrease In Other Noncurrent Assets | us-gaap/2024 | Other long-term assets | 1 |
| 0001628280-25-023460 | 6 | 20 | CF | 0 | H | Increase Decrease In Accounts Payable | us-gaap/2024 | Accounts payable | 0 |
| 0001628280-25-023460 | 6 | 21 | CF | 0 | H | Increase Decrease In Accrued Liabilities | us-gaap/2024 | Accrued expense and other current liabilities | 0 |
| 0001628280-25-023460 | 6 | 22 | CF | 0 | H | Increase Decrease In Operating Lease Liability | us-gaap/2024 | Operating lease liabilities | 0 |
| 0001628280-25-023460 | 6 | 23 | CF | 0 | H | Increase Decrease In Contract With Customer Liability | us-gaap/2024 | Deferred revenue | 0 |
| 0001628280-25-023460 | 6 | 24 | CF | 0 | H | Increase Decrease In Other Noncurrent Liabilities | us-gaap/2024 | Other long-term liabilities | 0 |
| 0001628280-25-023460 | 6 | 25 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash used in operating activities | 0 |
| 0001628280-25-023460 | 6 | 27 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2024 | Purchases of equipment | 1 |
| 0001628280-25-023460 | 6 | 28 | CF | 0 | H | Proceeds From Sale Of Property Plant And Equipment | us-gaap/2024 | Proceeds from the sale of property and equipment | 0 |
| 0001628280-25-023460 | 6 | 29 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash provided by (used in) investing activities | 0 |
| 0001628280-25-023460 | 6 | 31 | CF | 0 | H | Proceeds From Issuance Of Debt | us-gaap/2024 | Proceeds from the issuance of debt | 0 |
| 0001628280-25-023460 | 6 | 32 | CF | 0 | H | Payments Of Debt Issuance Costs | us-gaap/2024 | Payments of issuance costs related to BlackRock Credit Agreement | 1 |
| 0001628280-25-023460 | 6 | 33 | CF | 0 | H | Proceeds From Issuance Of Common Stock Net Of Issuance Costs | 0001628280-25-023460 | Proceeds from issuance of common stock, net of issuance costs | 0 |
| 0001628280-25-023460 | 6 | 34 | CF | 0 | H | Proceeds From Stock Plans | us-gaap/2024 | Proceeds from issuance of stock under employee stock purchase plan | 0 |
| 0001628280-25-023460 | 6 | 35 | CF | 0 | H | Proceeds From Stock Options Exercised | us-gaap/2024 | Proceeds from the exercise of stock options | 0 |
| 0001628280-25-023460 | 6 | 36 | CF | 0 | H | Repayments Of Debt | us-gaap/2024 | Repayment of term debt | 1 |
| 0001628280-25-023460 | 6 | 37 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash provided by financing activities | 0 |
| 0001628280-25-023460 | 6 | 38 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | Increase (decrease) in cash, cash equivalents and restricted cash | 0 |
| 0001628280-25-023460 | 6 | 39 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash, cash equivalents and restricted cash beginning of period | 0 |
| 0001628280-25-023460 | 6 | 40 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash, cash equivalents and restricted cash end of period | 0 |
| 0001628280-25-023460 | 6 | 42 | CF | 0 | H | Non Cash Financing Activities Issuance Of Warrants | 0001628280-25-023460 | Issuance of warrants in connection with BlackRock Credit Agreement | 0 |
| 0001628280-25-023460 | 6 | 43 | CF | 0 | H | Non Cash Financing Activities Unpaid Issuance Costs | 0001628280-25-023460 | Unpaid issuance costs related to BlackRock Credit Agreement | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |